Furthermore, they demonstrate that in a mouse model for acute lymphoblastic leukemia, treatment of mice with 17‐DMAG delays tumor progression and strikingly, this effect is only significant in AID‐proficient tumors, indicating that the efficacy of 17‐DMAG is largely attributable specifically to AID inhibition. This evidence concerns the gene AICDA and acute lymphoblastic leukemia.